Wedemeyer, H., Schöneweis, K., Bogomolov, P., Blank, A., Voronkova, N., Stepanova, T., . . . Urban, S. (2022). Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): A multicentre, randomised, parallel-group, open-label, phase 2 trial. The lancet. Infectious diseases, 23(1), . https://doi.org/10.1016/S1473-3099(22)00318-8
Chicago-Zitierstil (17. Ausg.)Wedemeyer, Heiner, et al. "Safety and Efficacy of Bulevirtide in Combination with Tenofovir Disoproxil Fumarate in Patients with Hepatitis B Virus and Hepatitis D Virus Coinfection (MYR202): A Multicentre, Randomised, Parallel-group, Open-label, Phase 2 Trial." The Lancet. Infectious Diseases 23, no. 1 (2022). https://doi.org/10.1016/S1473-3099(22)00318-8.
MLA-Zitierstil (9. Ausg.)Wedemeyer, Heiner, et al. "Safety and Efficacy of Bulevirtide in Combination with Tenofovir Disoproxil Fumarate in Patients with Hepatitis B Virus and Hepatitis D Virus Coinfection (MYR202): A Multicentre, Randomised, Parallel-group, Open-label, Phase 2 Trial." The Lancet. Infectious Diseases, vol. 23, no. 1, 2022, https://doi.org/10.1016/S1473-3099(22)00318-8.